New funding call for relapsed neuroblastoma research 

We’re excited to announce that our BEACON2 2025 Request for Applications (RFA) for grant funding is now open. 

This funding will support up to three pre-clinical studies into new drug combinations for treating relapsed neuroblastoma, with up to £250,000 available per project. These studies will play a crucial role in paving the way for better, less toxic treatments to reach the clinic. 

A key aim of this funding round is to ensure that the most impactful discoveries can feed directly into BEACON2, Europe’s largest clinical trial for children with relapsed neuroblastoma, helping accelerate progress and bring improved treatments to the children who need them most. 

Together with our wonderful funding partners – The Isla Caton Fund (a Family Fund held within Solving Kids’ Cancer UK), Villa Joep, and Children with Cancer UK – we’re driving change and working towards better treatments and brighter futures for every child with neuroblastoma.  

Children with relapsed neuroblastoma continue to face poor outcomes and limited treatment options. Through this funding call, we aim to drive research that delivers new and better options for these children and their families. 

FOCUS AREA: Late-stage translational research
BUDGET: Grants of up to £250,000 each
PROJECT DURATION: 2 years
DEADLINE: 16 February 2026 12:00 midday GMT

For the full details of this funding call and how to apply, download the Information Sheet and Application Form below.

Our funding partners